MSM 605
Alternative Names: MSM-605Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator MSM Protein Technologies
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma; Chronic obstructive pulmonary disease; Respiratory syncytial virus infections
Most Recent Events
- 06 Sep 2023 Preclinical development for Respiratory syncytial virus (RSV) infections, Chronic obstructive pulmonary disease and Asthma is ongoing in USA (MSM Protein Technologies pipeline, September 2023)
- 15 Jul 2016 MSM 605 is available for licensing -http://msmprotein.com/about/
- 15 Jul 2016 Preclinical trials in Asthma in USA (unspecified route)